These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28456566)

  • 1. Assessment of acute and chronic toxicity of doxorubicin in human induced pluripotent stem cell-derived cardiomyocytes.
    Louisse J; Wüst RCI; Pistollato F; Palosaari T; Barilari M; Macko P; Bremer S; Prieto P
    Toxicol In Vitro; 2017 Aug; 42():182-190. PubMed ID: 28456566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
    Burridge PW; Li YF; Matsa E; Wu H; Ong SG; Sharma A; Holmström A; Chang AC; Coronado MJ; Ebert AD; Knowles JW; Telli ML; Witteles RM; Blau HM; Bernstein D; Altman RB; Wu JC
    Nat Med; 2016 May; 22(5):547-56. PubMed ID: 27089514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
    Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
    Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
    Cunha-Oliveira T; Ferreira LL; Coelho AR; Deus CM; Oliveira PJ
    Toxicol Appl Pharmacol; 2018 Jun; 348():1-13. PubMed ID: 29653124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolite signatures of doxorubicin induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes.
    Chaudhari U; Ellis JK; Wagh V; Nemade H; Hescheler J; Keun HC; Sachinidis A
    Amino Acids; 2017 Dec; 49(12):1955-1963. PubMed ID: 28421296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin Cytotoxicity in Differentiated H9c2 Cardiomyocytes: Evidence for Acute Mitochondrial Superoxide Generation.
    Helal M; Alcorn J; Bandy B
    Cardiovasc Toxicol; 2021 Feb; 21(2):152-161. PubMed ID: 32910361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of in vitro models of stem cell-derived cardiomyocytes to screen for potential cardiotoxicity of chemicals.
    Shi M; Tien NT; de Haan L; Louisse J; Rietjens IMCM; Bouwmeester H
    Toxicol In Vitro; 2020 Sep; 67():104891. PubMed ID: 32446838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes.
    Chaudhari U; Nemade H; Sureshkumar P; Vinken M; Ates G; Rogiers V; Hescheler J; Hengstler JG; Sachinidis A
    Arch Toxicol; 2018 Jan; 92(1):371-381. PubMed ID: 28940058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
    Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
    Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes.
    Chaudhari U; Nemade H; Gaspar JA; Hescheler J; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Dec; 90(12):3087-3098. PubMed ID: 26842497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells.
    Holmgren G; Synnergren J; Bogestål Y; Améen C; Åkesson K; Holmgren S; Lindahl A; Sartipy P
    Toxicology; 2015 Feb; 328():102-11. PubMed ID: 25529476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
    Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
    J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing depending on SIRT3 activity attenuates doxorubicin-induced cardiotoxicity via elevated tolerance against mitochondrial dysfunction and oxidative stress.
    Yang N; Ma H; Jiang Z; Niu L; Zhang X; Liu Y; Wang Y; Cheng S; Deng Y; Qi H; Wang Z
    Biochem Biophys Res Commun; 2019 Sep; 517(1):111-117. PubMed ID: 31303273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The assessment of electrophysiological activity in human-induced pluripotent stem cell-derived cardiomyocytes exposed to dimethyl sulfoxide and ethanol by manual patch clamp and multi-electrode array system.
    Hyun SW; Kim BR; Hyun SA; Seo JW
    J Pharmacol Toxicol Methods; 2017 Sep; 87():93-98. PubMed ID: 28377112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes.
    Maillet A; Tan K; Chai X; Sadananda SN; Mehta A; Ooi J; Hayden MR; Pouladi MA; Ghosh S; Shim W; Brunham LR
    Sci Rep; 2016 May; 6():25333. PubMed ID: 27142468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin activates SIRT1 to protect human cardiomyocytes against doxorubicin-induced mitochondrial dysfunction and toxicity.
    Cui L; Guo J; Zhang Q; Yin J; Li J; Zhou W; Zhang T; Yuan H; Zhao J; Zhang L; Carmichael PL; Peng S
    Toxicol Lett; 2017 Jun; 275():28-38. PubMed ID: 28456571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of doxorubicin-induced cytotoxicity and mitochondrial damage by betanin in rat isolated cardiomyocytes and mitochondria.
    Hafez AA; Jamali Z; Samiei S; Khezri S; Salimi A
    Hum Exp Toxicol; 2021 Dec; 40(12):2123-2134. PubMed ID: 34105389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of gentamicin and penicillin/streptomycin on the electrophysiology of human induced pluripotent stem cell-derived cardiomyocytes in manual patch clamp and multi-electrode array system.
    Hyun SW; Kim BR; Lin D; Hyun SA; Yoon SS; Seo JW
    J Pharmacol Toxicol Methods; 2018; 91():1-6. PubMed ID: 29288713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.